SAM
PTCT icon

Silverback Asset Management’s PTC Therapeutics PTCT Stock Holding History

Silverback Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30,700
Closed -$820 – 44
2015
Q3 		$820 Buy
+30,700
New +$1.31M 0.09% 31

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Silverback Asset Management's PTCT Position: Q1 2016 in Review

Silverback Asset Management sold out of PTC Therapeutics (PTCT) in Q1 2016, closing a stake of 15,900 shares — an estimated $515K sold.

Silverback Asset Management first reported a position in PTCT in Q3 2015 and held it in 2 quarters. The position peaked at $515K in Q4 2015. 119 funds tracked by Wall St. Rank hold PTCT as of Q1 2016.

  • Silverback Asset Management reported no remaining PTC Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Silverback Asset Management sold 15,900 PTC Therapeutics shares in Q1 2016, an estimated $515K.
  • Silverback Asset Management first reported a position in PTC Therapeutics in Q3 2015 and held it in 2 quarters.
  • Silverback Asset Management's PTC Therapeutics position peaked at $515K in Q4 2015.
  • 119 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2016.

Based on Silverback Asset Management's 13F filing for Q1 2016, filed 13 May 2016.